Följ
norman stockbridge
norman stockbridge
Okänd anknytning
Verifierad e-postadress på stockbridges.org
Titel
Citeras av
Citeras av
År
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk
P Urban, R Mehran, R Colleran, DJ Angiolillo, RA Byrne, D Capodanno, ...
European heart journal 40 (31), 2632-2653, 2019
5052019
Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium
PT Sager, G Gintant, JR Turner, S Pettit, N Stockbridge
American heart journal 167 (3), 292-300, 2014
4672014
Developing therapies for heart failure with preserved ejection fraction: current state and future directions
J Butler, GC Fonarow, MR Zile, CS Lam, L Roessig, EB Schelbert, ...
JACC: Heart Failure 2 (2), 97-112, 2014
4062014
2017 cardiovascular and stroke endpoint definitions for clinical trials
KA Hicks, KW Mahaffey, R Mehran, SE Nissen, SD Wiviott, B Dunn, ...
Circulation 137 (9), 961-972, 2018
3762018
The comprehensive in vitro proarrhythmia assay (CiPA) initiative—update on progress
T Colatsky, B Fermini, G Gintant, JB Pierson, P Sager, Y Sekino, ...
Journal of pharmacological and toxicological methods 81, 15-20, 2016
3082016
Evolution of strategies to improve preclinical cardiac safety testing
G Gintant, PT Sager, N Stockbridge
Nature reviews Drug discovery 15 (7), 457-471, 2016
3072016
Concentration‐QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review
CE Garnett, N Beasley, VA Bhattaram, PR Jadhav, R Madabushi, ...
The Journal of Clinical Pharmacology 48 (1), 13-18, 2008
2312008
Differentiating drug‐induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil
L Johannesen, J Vicente, JW Mason, C Sanabria, K Waite‐Labott, ...
Clinical Pharmacology & Therapeutics 96 (5), 549-558, 2014
2012014
International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment
K Blinova, Q Dang, D Millard, G Smith, J Pierson, L Guo, M Brock, HR Lu, ...
Cell reports 24 (13), 3582-3592, 2018
1952018
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document
F Zannad, AA Garcia, SD Anker, PW Armstrong, G Calvo, JGF Cleland, ...
European journal of heart failure 15 (10), 1082-1094, 2013
1912013
Comprehensive translational assessment of human-induced pluripotent stem cell derived cardiomyocytes for evaluating drug-induced arrhythmias
K Blinova, J Stohlman, J Vicente, D Chan, L Johannesen, ...
Toxicological Sciences 155 (1), 234-247, 2017
1772017
Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
J Coresh, HJL Heerspink, Y Sang, K Matsushita, J Arnlov, BC Astor, ...
The lancet Diabetes & endocrinology 7 (2), 115-127, 2019
1552019
Cardiovascular drug development: is it dead or just hibernating?
CB Fordyce, MT Roe, T Ahmad, P Libby, JS Borer, WR Hiatt, MR Bristow, ...
Journal of the American College of Cardiology 65 (15), 1567-1582, 2015
1532015
New trial designs and potential therapies for pulmonary artery hypertension
M Gomberg-Maitland, TM Bull, R Saggar, RJ Barst, A Elgazayerly, ...
Journal of the American College of Cardiology 62 (25S), D82-D91, 2013
1492013
Results from the IQ‐CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase
B Darpo, C Benson, C Dota, G Ferber, C Garnett, CL Green, V Jarugula, ...
Clinical Pharmacology & Therapeutics 97 (4), 326-335, 2015
1472015
Dealing with global safety issues
N Stockbridge, J Morganroth, RR Shah, C Garnett
Drug safety 36 (3), 167-182, 2013
1452013
Clinical trial design and new therapies for pulmonary arterial hypertension
O Sitbon, M Gomberg-Maitland, J Granton, MI Lewis, SC Mathai, ...
European Respiratory Journal 53 (1), 2019
1342019
Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative
JP Piccini, DJ Whellan, BR Berridge, JK Finkle, SD Pettit, N Stockbridge, ...
American heart journal 158 (3), 317-326, 2009
1232009
Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil
J Vicente, L Johannesen, JW Mason, WJ Crumb, E Pueyo, N Stockbridge, ...
Journal of the American Heart Association 4 (4), e001615, 2015
1212015
Late sodium current block for drug‐induced long QT syndrome: results from a prospective clinical trial
L Johannesen, J Vicente, JW Mason, C Erato, C Sanabria, K Waite‐Labott, ...
Clinical Pharmacology & Therapeutics 99 (2), 214-223, 2016
1132016
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20